Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 072012
Deerfield, Ill., February 6, 2012 and Osaka, Japan, February 7, 2012 – Takeda Pharmaceutical Company Limited (Takeda) and its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc., today announced EDARBYCLOR (azilsartan medoxomil and chlorthalidone) is now available by prescription in U.S. pharmacies for the treatment of hypertension to lower blood pressure in adults. It is the only fixed-dose therapy in the U.S. to combine an angiotensin II receptor blocker (ARB) with chlorthalidone in a once-daily, single tablet. In a phase 3 clinical trial, the systolic blood pressure reductions of the maximum dose of EDARBYCLOR (40/25 mg), by both clinic and trough 24-hour ambulatory blood pressure monitoring, were shown to be statistically superior to those of the fixed-dose combination of olmesartan medoxomil-hydrochlorothiazide at its maximum dose (40/25 mg). Additionally, similar blood pressure lowering effects of EDARBYCLOR were observed in a sub-group analysis of black patients.
Feb 072012
Countries include Belgium, Finland, Iceland, Ireland, Luxembourg, the Netherlands, Norway, P...
Feb 062012
The RSS feed for this subscription is currently unavailable. Please try this subscription again later.
Feb 062012
Myriad Genetics to Present at the Leerink Swann 2012 Global Healthcare Conference